ImmunityBio’s IBRX stock has re-rated sharply as Anktiva transitions from a newly launched therapy to a product with accelerating prescriptions, expanding geographies, and active label-extension

ImmunityBio IBRX has entered a new phase as a commercial-stage immunotherapy developer. The company’s near-term trajectory is closely tied to a single asset, Anktiva, which now anchors both revenue

Amkor Technology AMKR is lining up for a pivotal second half of 2026 as structural artificial intelligence (AI) and high-performance computing (HPC) demand accelerates advanced packaging activity

Between spring and summer of last year, Oracle (ORCL) stock nearly tripled as maverick founder and CEO Larry Ellison laid everything on the line to join the AI race. The stock surged from under $130

CRH plc CRH is often framed as a beneficiary of U.S. roads and bridges spending, but a quieter demand driver is building alongside it. Digital infrastructure is emerging as a meaningful throughput

Lennar Corporation LEN reported tepid results for the first quarter of fiscal 2026, wherein its adjusted earnings and total revenues missed the Zacks Consensus Estimate and declined year over

CRH plc CRH sits at an interesting crossroads. The stock trades at a discount to broad benchmarks, yet its near-term earnings narrative is getting tougher as estimates drift lower. At the same time

MP Materials MP is trading at a forward 12-month price/sales multiple of 20.95X, a significant premium to the industry’s 1.43X. It has a Value Score of F, which suggests that the stock appears

FormFactor’s FORM shares have surged 187.8% in the trailing six months, outperforming the broader Zacks Computer and Technology sector’s growth of 0.3% and the Zacks Electronics- Semiconductors